medigraphic.com
ISSN 1727-897X (Electronic)

2022, Number 3

<< Back Next >>

Medisur 2022; 20 (3)

Immunohistochemical subtypes and their relationship with the clinicopathological and histological aspects of breast cancer

González-Longoria BL, González PS, López-Muñoz F

Language: Spanish
References: 22
Page: 478-486
PDF size: 322.43 Kb.


ABSTRACT

Background: The prognosis and therapy of breast cancer (BC) is closely related to the histopathological characteristics of the patient. These allow to establish prognostic groups, as support in the decision of effective individual treatments. However, the existing information is limited on the relationship between these aspects and the immunohistochemical subtypes (IHC) of breast cancer in Latin American countries.
Objective: To determine the relationship between the clinical-pathological and histological characteristics with the IHC subtypes of BC in Ecuadorian patients.
Methods: An observational of the cross-sectional study was carried out in Ecuadorian patients treated at the Abel Gilbert Pontón Hospital between January 2014 and December 2017. 199 patients with a histopathological diagnosis of BC were included. Clinicopathological variables were analyzed: age, tumor size and lymph node status; histological: type and histological grade.
Results: The mean age of the patients was 56,77 ± 11,96 years. Lymph node metastases were observed in most cases (63,3%). The mean tumor size was 3,88 ± 1,61 cm. More than half of the cases (56,8%) presented a moderately differentiated histological grade. The predominant molecular subtype was Luminal A neoplasia (53,8%). The analysis showed a significant association (p <0, 0001) between IHC subtypes and the clinicopathological and histological characteristics of BC.
Conclusions: Breast neoplasia in Ecuadorian patients is diagnosed in advanced stages. The study emphasizes the need to introduce IHC receptor tests into clinical practice to help determine the biology of breast cancer, improve the effect on therapy and the patient's prognosis.


REFERENCES

  1. Organización Mundial de la Salud. Cáncer de mama[Internet]. Washington: OMS; 2021[citado 4/7/2021]. Disponible en: https://www.who.int/es/news-room/fact-sheets/detail/breast-cancer

  2. Peñate FD, de la Torre A. El autoexamen y la detección precoz del cáncer de mama. Medicentro Electrónica[Internet]. 2018[citado 23/06/2021];22(1):[aprox. 3 p.]. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1029-304320180001000172.

  3. Yanagawa M, Ikemot K, Kawauchi S, Furuya T, Yamamoto S, Oka M, et al. Luminal A and luminal B (HER2 negative) subtypes of breast cancer consist of a mixture of tumors with different genotype. BMC Research Notes. 2012;5(1):1-8.

  4. Da Silva K, Dittrich M. Tecnologia em arteterapia para à saúde de pessoas com cancer de mama. Saúde & Transformação Social/Health & Social Change. 2014;5(3):10-19.

  5. Coates A, Winer E, Goldhirsch A, Gnant M, Piccart-Gebhart M, et al. Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Annals Oncology. 2015;26(8):1533-46.

  6. Subik K, Lee J, Baxter L, Strzepek T, Costello D, Crowley P, et al. The expression patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by immunohistochemical analysis in breast cancer cell lines. Breast Cancer (Auckl). 2010;4:35-41.

  7. Osorio N, Bello C, Vega L. Factores de riesgo asociados al cáncer de mama. Revista Cubana de Medicina General Integral. 2020;36(2):e1147.

  8. Martínez J, Socorro C. Inmunohistoquímica en el cáncer de mama. Herramienta necesaria en la actualidad. Medisur[Internet]. 2018[citado 23/06/2021]; 16(1):[aprox. 4 p.]. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1727-897X20180001000168.

  9. Sohn Y, Han K, Seo M. Immunohistochemical Subtypes of Breast Cancer: Correlation with Clinicopathological and Radiological Factors. Iran J Radiol. 2016;13(4):e31386.

  10. Widodo I, Dwianingsih E, Anwar S, Triningsih F, Utoro T, Aryandono T. Prognostic Value of Clinicopathological Factors for Indonesian Breast Carcinomas of Different Molecular Subtypes. Asian Pac J Cancer Prev. 2017; 18(5):1251-56.

  11. Edge S, Byrd D, Compton C, Fritz A, Greene F, Trotti A. AJCC Cancer Staging Manual. 7th ed. Chicago: Springer; 2010.

  12. Medina G. Características clínicas y pronósticas de los subtipos moleculares de cáncer de mama determinados por inmunohistoquímica. Arequipa, Perú. Rev Peru Med Exp Salud Publica. 2017;34(3):472-77.

  13. Simón S, Bines J, Werutsky G, Soares J, Chalu F, Getúlio J, et al. Characteristics and prognosis of stage I-III breast cancer subtypes in Brazil: The AMAZONA retrospective cohort study. The Breast. 2019;44:113-19.

  14. Caldarella A, Buzzoni C, Crocetti E, Bianchi S, Vezzosi V, Apicella P, et al. Invasive breast cancer: a significant correlation between histological types and molecular subgroups. J Cancer Res Clin Oncol. 2013;139(4):617-23

  15. Spitale A, Mazzola P, Soldini D, Mazzucchelli L, Bordon A. Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the South of Switzerland. Annals Oncology. 2009;20(4):628-35.

  16. Ulloa P, Ronquillo S, Sánchez K. Sobrevida en pacientes con cáncer de mama según su inmunohistoquímica: experiencia del Instituto Oncológico Nacional - Sociedad de Lucha Contra el Cáncer, Guayaquil, Ecuador. Rev Méd Sinerg. 2020;5(7) :e542.

  17. Vela D, Salazar S, Salazar D. Frecuencia de subtipos moleculares de cáncer de mama, Hospital Metropolitano, 2016-2019, Quito-Ecuador. Metro Ciencia. 2020;28(3):32-8.

  18. Lebert J, Lester R, Powell E, Seal M, McCarthy J. Advances in the systemic treatment of triple-negative breast cancer. Current Oncology. 2018;25(1):142-50.

  19. Adani-Ifè A, Amégbor K, Doh K, Darré T. Breast cancer in togolese women: immunohistochemistry subtypes. BMC Women's Health. 2020;20(1):1-7.

  20. Mwakigonja A, Lushina N, Mwanga A. Characterization of hormonal receptors and human epidermal growth factor receptor-2 in tissues of women with breast cancer at Muhimbili National Hospital, Dar es salaam, Tanzania. Infect Agent Cancer. 2017;12:60.

  21. Akbar M, Akbar K, Naveed D. Frequency and correlation of molecular subtypes of breast cancer with clinicopathological features. J Ayub Med Coll Abbottabad. 2014;26(3):290-3.

  22. Sengal A, Haj-Mukhtar N, Elhaj A, Bedri S, Kantelhardt E, Mohamedani A. Immunohistochemistry defined subtypes of breast cancer in 678 Sudanese and Eritrean women; hospitals based case series. BMC Cancer. 2017;17(1):1-9.




2020     |     www.medigraphic.com